从升级到升级:全面心脏性冲击管理的新范式
Darshan H Brahmbhatt1, Sanjog Kalra2, Adriana Luk2
1Division of Cardiology, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada; Ted Rogers Centre for Heart Research, University Health Network, Toronto, Ontario, Canada; Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
The Canadian journal of cardiology
|January 11, 2025
概括
本综述讨论了目前对心脏性休克 (CS) 的治疗方法,这是一种心脏输出量 (CO) 低的情况. 它提出了一种新的,即时的治疗方法,以快速逆转休克并改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 血液动力学 血液动力学
背景情况:
- 心脏性休克 (CS) 是一种危急状况,其特点是心脏输出量 (CO) 低和末端器官功能障碍.
- 在CS患者的预后与休克严重程度密切相关,需要密集的资源管理.
- 目前的CS治疗依赖于反应性,基于反的方法,导致干预的延迟.
研究的目的:
- 审查心脏性休克 (CS) 的当前治疗模式.
- 引入一种新的,主动的治疗策略,以快速改善休克状态.
- 为评估CS干预提出新的绩效指标.
主要方法:
- 对现有的心脏性休克 (CS) 治疗策略的文献综述.
- 概念化一种新的,即时干预方法,用于CS.
- 关于新指标的建议,用于评估CS中的治疗疗效.
主要成果:
- 目前的CS治疗方法涉及渐进的调整,可能会延长休克状态.
- 一种新的方法强调立即,果断的干预,以迅速扭转CS.
- 拟议的战略旨在更有效地"打破"冲击螺旋.
结论:
- 标准的CS治疗的反机制可能会导致严重的延迟.
- 积极主动的,即时的治疗策略可能在心脏性休克中提供更好的结果.
- 需要新的绩效指标来评估快速CS干预措施的有效性.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
745
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
745
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: Inotropic Agents
511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
Pathophysiology of Cardiac Performance
525
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
525


